The abstract is read at the publisher; the summary is JClub's.
Regionally coordinated DNA methylation changes across multiple time points during eight weeks of antidepressant treatment in 162 MDD patients are linked to clinical response.
- Why it matters: Response to antidepressants varies in major depressive disorder, and prior cross-sectional epigenome-wide association findings are inconsistent, leaving a gap for longitudinal molecular markers.
- What they did: In the Early Medication Change trial, longitudinal EWAS with comb-p modeled differentially methylated positions and regions across four patient assessments and two control assessments, using 81 responders, 81 non-responders, and 48 matched healthy controls.
- The result: Baseline methylation related to symptom severity at day 28 and day 56 via two and six DMRs, while longitudinal models found one DMP (YLMP1) and three DMRs with time-linked changes (e.g., GPR126, PM20D1), plus additional diagnosis and temporal effects in combined analyses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.